Intervet develops prototype for mass application avian influenza vaccine
The new prototype vaccine consists of a safe live vaccine against Newcastle Disease (a condition affecting many bird species), which acts as a carrier for the haemagglutinin gene-the vital genetic material needed to build immunity against the avian influenza virus.
The new vaccine-which is scheduled to undergo field trials next year-can also be used on large numbers of birds as an efficient marker vaccine to help differentiate between infected and vaccinated birds.
Organizations
Other news from the department science
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.